Locoregional adoptive immunotherapy resulted in regression in distant metastases of a recurrent esophageal cancer

International Journal of Clinical Oncology

Volumn 7, Issue 6, 2002, Pages 372-375

  Toh, Uhi ^a   Sudo, Tomoya ^a   Kido, Kouichiro ^a   Matono, Satoru ^a   Sasahara, Hiroko ^a   Mine, Takashi ^a   Tanaka, Toshiaki ^a   Sueyoshi, Susumu ^a   Fujita, Hiromasa ^a   Shirouzu, Kazuo ^a   Yamana, Hideaki ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Esophageal cancer; Intratumoral injection; Locoregional immunotherapy

Indexed keywords

CISPLATIN; FLUOROURACIL; IMMUNOMODULATING AGENT; INTERLEUKIN 2;

ABDOMINAL AORTA; ADOPTIVE IMMUNOTHERAPY; ADULT; ADVANCED CANCER; ARTICLE; AUTOLOGOUS TUMOR ACTIVATED LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; DIARRHEA; DRUG CYTOTOXICITY; ESOPHAGUS CANCER; FEVER; HUMAN; LIVER; LYMPH NODE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFER; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; METASTASIS INHIBITION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE RISK; REGIONAL PERFUSION; SUPRACLAVICULAR LYMPH NODE; TREATMENT OUTCOME;

ANTIGENS, CD; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS; LYMPH NODES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 0036938232     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101470200058     Document Type: Article

References (15)

1. Chang AE, Aruga A, Cameron MJ, et al. (1987) Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 15:796-807
2. Rosenberg SA, Lotze MT, Muul LM, et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316:889-897
3. Fisher RI, Coltman CA Jr, Doroshow JW, et al. (1988) Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells - a phase II clinical trail. Ann Intern Med 108:518-523
4. Toh U, Yamana H, Sueyoshi S, et al. (2000) Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res 6:4663-4673
5. Toh U, Yamana H, Nakao M, et al. (1997) HLA class I-restricted and tumor-specific cytotoxic T lymphocytes from metastatic lymph nodes of esophageal cancers. Cell Immunol 177:137-143
6. Toh U, Yamana H, Fujita H, et al. (1998) Establishment of HLA-class I restricted and tumor-specific CTLs in patients with esophageal cancers. Biotherapy 12:56-61
7. Akaishi T, Sekine Y, Sanekata K, et al. (1986) Characteristics of growth and effectiveness of anti-cancer drugs on tissue cultured human esophageal cancer cells. In: Kasai M (ed) Esophageal cancer: proceedings of the International Symposium on Cancer of the Esophagus. Excerpta Medica, Amsterdam, pp 35-38
8. Aruga A, Shu S, Chang AE (1995) Tumor-specific granulocyte/ macrophage colony-stimulating factor and interferon-secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells. Cancer Immunol Immunother 41:317-324
9. + killer cells. Ann Hematol 74:51-56
10. Kjaergaard J, Hokland M, Nannmark U, et al. (1998) Infiltration patterns of short- and long-term cultured A-NK and T-LAK cells following adoptive immunotherapy. Scand J Immunol 47:532-540
11. Basse P, Herberman RB, Nannmark U, et al. (1991) Accumulation of adoptively transferred adherent lymphkine-activated killer cells in murine metastases. J Exp Med 174:479-488
12. Basse P, Nannmark U, Johansson BR, et al. (1991) Establishment of cell-to-cell cantact by adoptively transferred adherent lymphokine-activated killer cells with metastatic murine melanoma cells. J Natl Cancer Inst 83:944-950
13. Rosenberg SA, Spiess P, Yang JC, et al. (1989) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Ann Surg 210:474-485
14. Zoll B, Lefterova P, Csipai M, et al. (1998) Generation of cytokine-induced killer cells using exogenous interleukin-2, -7, or -12. Cancer Immunol Immunother 47:221-226
15. Burger UL, Chang MP, Goedegebuure PS, et al. (1995) Recruitment of host CD8+ T cells by tumor-infitrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer. Surgery 117:325-333